Natera, Inc.
Natera, Inc.
Explore linked clinical trials.45 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gallbladder adenocarcinoma, gastric adenocarcinoma, hepatocellular carcinoma, intestinal disorder, liver disorder, neoplasm, pancreatic adenocarcinoma, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-06 | NCT05482516 | |
| Trifecta-Heart cfDNA-MMDx Study | Heart Transplant Rejection | Recruiting | Not stated | 2026-10-06 | NCT04707872 | |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2026-10-05 | NCT07290985 | |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT06500273 | |
| A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy | Muscle-invasive Bladder Cancer | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04660344 | |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Carcinoma, Ductal, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast ductal adenocarcinoma, breast neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-09-23 | NCT07214532 | |
| Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, gastroesophageal adenocarcinoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-09-21 | NCT06529822 | |
| Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Recruiting | Not stated | 2026-09-16 | NCT05081024 | |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-02 | NCT05174169 | |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-09-01 | NCT07502872 | |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkin Lymphoma, Adult, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-08-20 | NCT07021989 | |
| ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-08-19 | NCT07084558 | |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not stated | 2026-08-13 | NCT07763197 | |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, non-Hodgkin lymphoma | Recruiting | Not stated | 2026-08-06 | NCT07750886 | |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary system disorder | Not yet recruiting | Not applicable | 2026-08-04 | NCT07689812 | |
| Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) | Immunosuppresion; Kidney Transplant | Not yet recruiting | Not applicable | 2026-07-22 | NCT07718633 | |
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2026-07-22 | NCT07340567 | |
| Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 3 | 2026-07-21 | NCT07717450 | |
| Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-07-21 | NCT06450314 | |
| Trifecta-Lung cfDNA-MMDx Study | Lung Transplantation | Recruiting | Not stated | 2026-07-17 | NCT05837663 | |
| Signatera Assessment in Early-Stage Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Not applicable | 2026-06-17 | NCT07339384 | |
| Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors | Germ Cell Cancer Metastatic | Recruiting | Not applicable | 2026-06-15 | NCT07401316 | |
| Trifecta-Kidney cfDNA-MMDx Study | Kidney Transplant Rejection | Recruiting | Not stated | 2026-06-02 | NCT04239703 | |
| Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-05-11 | NCT04920032 |